Skip to main content

Table 2 Skin status at first evaluation examination

From: The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

  IM IFNβ-1a
(n = 82)
SC IFNβ-1b
(n = 123)
SC IFNβ-1a
(n = 184)
SC GA
(n = 23)
Overall
(N = 412)
Any ISR, n (%) 11 (13.4) 71 (57.7) 125 (67.9) 7/23 (30.4) 214 (51.9)
Necrosis, n (%) 0 (0)a 7 (5.7) 11 (6.0) 0 (0) 18 (4.4)
Number of occurrences      
   1 0 1/7 (14.3) 6/11 (54.5) 0 7/18 (38.9)
   2 0 4/7 (57.1) 3/11 (27.3) 0 7/18 (38.9)
   3 0 1/7 (14.3) 1/11 (9.1) 0 2/18 (11.1)
   4 0 1/7 (14.3) 0 0 1/18 (5.6)
   Unknown 0 0 1/11 (9.1) 0 1/18 (5.6)
Severity      
   Mild 0 3/7 (42.9) 6/11 (54.5) 0 9/18 (50.0)
   Moderate 0 3/7 (42.9) 3/11 (27.3) 0 6/18 (33.3)
   Severe 0 1/7 (14.3) 1/11 (9.1) 0 2/18 (11.1)
   Unknown 0 0 1/11 (9.1) 0 1/18 (5.6)
Lipoatrophy, n (%) 1 (1.2)b 11 (8.9) 19 (10.3) 3 (13.0) 34 (8.3)
Number of occurrences      
   1 0 1/11 (9.1) 5/19 (26.3) 1/3 (33.3) 7/34 (20.6)
   2 0 6/11 (54.5) 6/19 (31.6) 1/3 (33.3) 13/34 (38.2)
   3 0 2/11 (18.2) 2/19 (10.5) 1/3 (33.3) 5/34 (14.7)
   4 1/1 (100) 0 0 0 1/34 (2.9)
   ≥5 0 2/11 (18.2) 6/19 (31.6) 0 8/34 (23.5)
Severity      
   Mild 1/1 (100) 6/11 (54.5) 10/19 (52.6) 2/3 (66.7) 19.34 (55.9)
   Moderate 0 2/11 (18.2) 9/19 (47.4) 1/3 (33.3) 12/34 (35.3)
   Severe 0 1/11 (9.1) 0 0 1/34 (2.9)
   Unknown 0 2/11 (18.2) 0 0 2/34 (5.9)
Injection omitted during last 4 weeks, n (%) 0 (0)c 7 (5.7) 13 (7.1) 1 (4.3) 21 (5.1)
  1. At the first evaluation examination, patients had been on their current DMT for at least 2 years.
  2. a P = 0.028 vs SC IFNβ-1b; P = 0.020 vs SC IFNβ-1a.
  3. b P = 0.021 vs SC IFNβ-1b; P = 0.009 vs SC IFNβ-1a; P = 0.032 vs SC GA.
  4. c P = 0.044 vs SC IFNβ-1b; P = NS vs SC GA; P = 0.011 vs SC IFNβ-1a.